Abstract
A critical appraisal and clinical application of
Hauser RA, Factor SA, Marder SR, et al. KINECT 3: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Valbenazine for Tardive Dyskinesia. Am J Psychiatry. 2017;174(5):476-484. https://doi.org/10.1176/appi.ajp.2017.16091037
and
Factor SA, Remington G, Comella CL, et al. The Effects of Valbenazine in Participants with Tardive Dyskinesia: Results of the 1-Year KINECT 3 Extension Study. J Clin Psychiatry. 2017;78(9):1344-1350. https://doi.org/10.4088/JCP.17m11777
exploring the efficacy of a newer therapy for tardive dyskinesia, and describing recommendations for a patient with acute medical problems and longstanding tardive dyskinesia.
DOI
10.22237/crp/1586477040
Creative Commons License
This work is licensed under a Attribution 4.0 International (CC-BY 4.0) License
Recommended Citation
FRIEDLI J, QUICK R, SOBH R, COWING S. Valbenazine has a small but meaningful benefit for tardive dyskinesia. Clin. Res. Prac. Apr 22 2020;6(1):eP2104. https://doi.org/10.22237/crp/1586477040
Included in
Medical Education Commons, Nervous System Diseases Commons, Psychiatry Commons, Translational Medical Research Commons
